Top Tweets for #ada25
@DrNadolsky @tmodarressi @GoggleDocs @Ali_Aminian_MD @AmarPut @drkevinfernando @HannahBeba @DSNforumUK @CristobMorales @pabeda1 @cristinatejerap @_DipeshPatel @docwas @AskDrShashank STEP-UP trial testing semaglutide 7.2mg vs 2.4mg. Dysesthesia rates 22.9% vs 6%. via #ADA25
🔴Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 ⤵️ #openaccess via #ADA25
🔹https://t.co/RvvBJPZlRq
#Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros #MedX
Grateful for the opportunity to present our poster on diabetic ischaemic heart disease at #ADA2025 in Chicago. I would like to thank my co-authors @akaakole_mensah @KwaahPatrick and program @ImWvu for their continuous support.
@wvudeptofmed #ADA25 #MedTwitter #Cardiology
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: William Blair analyst Andy Hsieh puts odds on Lilly’s pill orforglipron succeeding in obesity after seeing diabetes data at #ADA25 in Chicago.
Hear all of his ADA takeaways here: https://t.co/EP0sOp3pCI
Andy attended #ADA25 and gives a rundown of Orforglipron, Bimagrumab, CagriSema, MariTide, and more.
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: @WilliamBlair biotech analyst Andy Hsieh takes stock of the obesity space after attending #ADA25 in Chicago.
$LLY $NVO $AMGN $VKTX
Full video: https://t.co/EP0sOp3pCI
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: @WilliamBlair biotech analyst Andy Hsieh takes stock of the obesity space after attending #ADA25 in Chicago.
$LLY $NVO $AMGN $VKTX
Full video: https://t.co/EP0sOp3pCI
Novo Nordisk $NVO, seen as lagging in obesity drug race, says it’s playing the long game
@elainechen spoke with Novo execs while at #ADA25
https://t.co/9gMxHPCiwV
🔴Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 ⤵️ #openaccess via #ADA25
🔹https://t.co/RvvBJPZTGY
#Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros
$SANA data just came in - now two paths to a T1D cure - both just showed progress at #ADA25
$VRTX zimislecel (VX-880)
🔹 10 of 12 patients insulin-free at 12 months
🔹 Requires immunosuppression
🔹 Cadaveric islets, aiming to scale with stem cell–derived product (VX-264, in capsule)
$SANA HIP-islets (UP421)
🔹 1st pt: sustained C‑peptide & MMTT response at 6 mon
👉No immunosuppression used👈
🔹 HIP-edited donor islets
$SANA must scale from scarce donor islets to high-yield PSC lines, while keeping tumor risk near zero
https://t.co/bJ95glJczL
1/ The First T1D Functional Cure Is Here
Vertex just dropped 1-year data for zimislecel (VX-880) in Type 1 diabetes. #ADA2025
✅ Cures in 10 out of 12 patients
✅ 83% insulin independence
✅ 100% C-peptide reactivation
✅ 0 severe hypoglycemic events after Day 90
This is the first real shot at a functional cure.
But how does it compare to $SANA?
👇🏼
Early-onset type 2 diabetes remains under-researched and undertreated.
A new Series, presented at #ADA25, synthesises emerging evidence, highlighting urgent research gaps, and calls for population-level prevention & tailored care.
Explore the Series 👉 https://t.co/YEbhFtMXGt
#ADA25: Updated data from Novo's amycretin reveals perplexing lack of response in higher doses.
https://t.co/csVRmnHAz2
Novo Nordisk’s $NVO amylin obesity drug keeps performing like $LLY Zepbound https://t.co/NVKQt3PyE1 via @elaineywchen #ADA25
Busy day for $NVO at #ADA25 (Sun, June 22 – CDT / Copenhagen time):
8:00 AM CDT / 3:00 PM CEST: Phase 3 results for CagriSema (REDEFINE 1 & 2)
10:15 AM CDT / 5:15 PM CEST: R&D Investor Event webcast (Wegovy 7.2 mg, amycretin, SOUL & more)
4:30 PM CDT / 11:30 PM CEST: SOUL trial presentation (CV outcomes for oral semaglutide)
#StocksToWatch #InvestingTips
A puzzling update from Novo Nordisk and new data from Roche at #ADA25 - https://t.co/JDZIiv8uqs
$NVO $LLY $AZN $SNY
$GSK $PFE $RHHBY $ZLDPF
$VKTX $VANI $HIMSv
Lilly's oral GLP-1 dodges side effect minefield that sunk Pfizer drug $LLY #ADA25 https://t.co/LPsDd67V5A
$NVO results from Phase 3b STEP UP trial showed that higher dose of Wegovy (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight vs. placebo. $LLY $VKTX #ADA25
https://t.co/L7CtJ5JBFJ
$VRTX Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions. #ADA25 https://t.co/iZr82FhCTO
$NVO $NOVOB Higher dose of Wegovy provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at #ADA25. $LLY
$NVO $NOVOB subcutaneous and oral amycretin data published in The Lancet and presented at #ADA25. $LLY
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.3M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.1M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.3M followers
KATY PERRY
@katyperry
88.6M followers
Taylor Swift
@taylorswift13
82.5M followers
Lady Gaga
@ladygaga
74M followers
Virat Kohli
@imvkohli
71.4M followers
Kim Kardashian
@kimkardashian
70.2M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.4M followers
Neymar Jr
@neymarjr
64.3M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.7M followers
X
@x
60.8M followers